Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects Triolex (He3286) As A Oral Anti-Inflammatory Drug Candidate

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced that Cystic Fibrosis Foundation Therapeutics, Inc, (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, has selected Hollis-Eden’s TRIOLEX? (HE3286) as a drug candidate for lung inflammation associated with cystic fibrosis (CF) under their existing collaboration agreement. [click link for full article]

More: continued here

Filed under: Cystic Fibrosis on December 24th, 2007